Senvest Management LLC Has $1.18 Million Holdings in uniQure N.V. $QURE

Senvest Management LLC increased its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 44.6% during the first quarter, Holdings Channel.com reports. The fund owned 72,300 shares of the biotechnology company’s stock after purchasing an additional 22,300 shares during the quarter. Senvest Management LLC’s holdings in uniQure were worth $1,182,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of QURE. Torren Management LLC acquired a new position in shares of uniQure during the 4th quarter worth approximately $28,000. IFP Advisors Inc bought a new position in shares of uniQure during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the third quarter valued at approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 906 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

NASDAQ QURE opened at $38.97 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -11.20 and a beta of 0.90. The firm’s 50 day simple moving average is $35.94 and its 200 day simple moving average is $25.66. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, research analysts expect that uniQure N.V. will post -3.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on QURE shares. Royal Bank Of Canada increased their price target on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Leerink Partners lifted their price objective on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Finally, Mizuho raised their price target on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $64.17.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 21,082 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total transaction of $952,063.12. Following the completion of the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. The trade was a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the sale, the director owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 433,229 shares of company stock worth $17,944,799. 4.65% of the stock is owned by company insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.